US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second quarter (Q2) of fiscal year 2025, which concluded on October 25, 2024. The company reported a total revenue of USD 8.403 billion for the period, marking a 5.0% increase on an organic basis.
Cardiovascular Portfolio Leads the Way with 5.6% Organic Growth
Medtronic’s Cardiovascular Portfolio, encompassing the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions, achieved sales of USD 3.102 billion, demonstrating a robust 5.6% organic growth. This performance indicates a strong market response to the company’s cardiovascular offerings.
Neuroscience Portfolio Achieves 6.7% Organic Growth
The Neuroscience Portfolio, which includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions, recorded sales of USD 2.451 billion, representing a significant 6.7% organic growth. CST, in particular, exceeded average market performance due to the ongoing adoption of the AiBLE ecosystem of spine implants and enabling technology, a testament to Medtronic’s innovation in neurosurgical solutions.
Medical Surgical and Diabetes Portfolios Also Show Growth
The Medical Surgical Portfolio and Diabetes divisions contributed revenues of USD 2.128 billion and USD 686 million, respectively, with organic growth rates of 0.7% and 11%. These results reflect the company’s ability to deliver consistent growth across its diverse product offerings.-Fineline Info & Tech
Leave a Reply